Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-PM-PBB3 PET in Tauopathy
NCT03625128Phase 1Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jan 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florzolotau in Alzheimer's disease (AD), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and 2 more, sponsored by Chang Gung Memorial Hospital. Primary endpoint: Dosimetry of novel radiotracer 18F-PM-PBB3 at 1 year. Started Jan 2018; status: completed.
02
Drugs
florzolotau
03
Conditions
Alzheimer's disease (AD)frontotemporal dementia (FTD)progressive supranuclear palsy (PSP)Corticobasal Syndrome (CBS)vascular cognitive impairment (VCI)
Beyond the preview
Go deeper on NCT03625128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625128.